ModeX is dedicated to developing next-generation multispecific biologics for cancers and infectious diseases.
ModeX’s platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency against complex diseases.
Foundations for leadership
We are a leading developer of multispecific biologics. Our capabilities are built on decades of collaboration amongst our team at the highest levels of medical research. We have achieved several breakthroughs in recent years that drive our work to create medicines that save lives.
ModeX becomes a wholly owned subsidiary of OPKO Health, a diverse healthcare company focused on improving patients’ lives
ModeX vaccine R&D is published in Science Translational Medicine, describing the ability of our EBV ferritin nanoparticle vaccine technology to induce neutralizing antibodies that block infection and confer immunity
ModeX immuno-oncology R&D is published in Nature, describing the anti-tumor activity of one of our trispecific T-cell engager antibodies
ModeX welcomes new industry-leading leadership including John Mascola as Chief Scientific Officer, Ji Zhang as Chief Operating Officer and Vijay Chhajlani as Chief Technology Officer
ModeX reveals its two core multispecific antibody platforms: MSTAR (Synergistic Targeting of Antigens and Receptors), and STEALTH for tumor-specific activation
ModeX initiates clinical study of first-generation trispecific antibody technology against HIV
ModeX is founded by eminent medical innovators Gary Nabel and Elias Zerhouni as well as R&D leaders Zhi-yong Yang, Ronnie Wei, Chih-Jen Wei and Elizabeth Nabel
While at Sanofi, the team creates a trispecific antibody that engages three targets with a single antibody
Drs. Elias Zerhouni and Gary Nabel create Breakthrough Laboratories within Sanofi Global R&D to explore first-in-class technologies and concepts
Leading with experience
OPKO Health, President and Vice Chairman of the Board of Directors
OPKO Health, Chief Innovation Officer and Board Director
In May 2022, we merged with OPKO Health to begin a major new phase for both companies as a united entity with a shared vision for transforming medicine. Over decades, OPKO Health has built a diversified business under the oversight of Dr. Philip Frost, a successful physician entrepreneur, and an experienced leadership team. ModeX brings to OPKO groundbreaking multispecific biologic platforms and expertise through our management team’s world-leading biomedical innovation leadership.
In combination with OPKO’s deep operational and development capabilities, we are strongly positioned together to move multiple programs in parallel through clinical development and accelerate our strategy to deliver a portfolio of first-in-class multispecific biologics for cancer and infectious disease.